VBI Vaccines Inc (VBIV) is up 16.37% today even as no major news has been announced recently about the company. Investors are seemingly speculating on which biotech stock to buy that may provide a vaccine for the COVID-19 virus that is having major effects on daily life at the moment. The stock had been trending downward until Tuesday in which its share price went up over 21% as market sentiment shifted. The volume for the stock was at 23 million yesterday as opposed to its average trading of 14 million. This has been a trend in recent months with investors trying to pick the correct “lottery ticket” and choose the company that will make advancements in a potential vaccine.
VBIV stock has risen 329.67% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserver’s proprietary scoring system, gives VBIV stock a score of 89 out of a possible 100.
That score is primarily influenced by a long-term technical score of 99. VBIV’s score also includes a short-term technical score of 91. The fundamental score for VBIV is 75. In addition to the average rating from Wall Street analysts, VBIV stock has a mean target price of 5.5. This means analysts expect the stock to rise 40.66% over the next 12 months.
What’s Happening with VBIV Stock Today
VBI Vaccines Inc (VBIV) stock has risen 16.37% while the S&P 500 has risen 0.78% as of 10:03 AM on Wednesday, Jul 8. VBIV has risen $0.55 from the previous closing price of $3.36 on volume of 16,184,931 shares. Over the past year the S&P 500 has risen 6.39% while VBIV has risen 329.67%. VBIV lost -$0.40 per share in the over the last 12 months.
